We continue our series in the Biologics campaign – now it is devoted to Sodium-glucose co-transporter 2 (SGLT2).
Sodium-dependent glucose co-transporters (SGLTs) are involved in transporting glucose molecules across membranes against a concentration gradient together with the movement of sodium ions down the concentration gradient. SGLTs are classified into SGLT1 and SGLT2. SGLT2 is a high-capacity, low-affinity transporter. It is located on the luminal surface of epithelial cells of the proximal convoluted tubules in the kidneys. Most of the renal glucose reabsorption is promoted by SGLT2. Now SGLT2 has attracted significant attention as a new target for type 2 diabetes (T2D) treatment.
You can find more information about this target here.
Diabetes type 2 is a rapidly growing metabolic disorder and over 400 million people worldwide suffer from it. Several SGLT2 inhibitors have been approved for clinical use during the last decades but drugs with better parameters are required. Recent investigations in discovering new potent and selective SGLT2 inhibitors led to a promising candidate for development as an anti-diabetic agent with excellent behavior in animal models.
More information about this research is here.
_SGLT_2.png)